Literature DB >> 22201783

Liver transplantation in chronic cholestatic conditions.

Piotr Milkiewicz1, Ewa Wunsch, Elwyn Elias.   

Abstract

Primary biliary cirrhosis and primary sclerosing cholangitis are two most frequently encountered cholestatic condition in adults. Liver transplantation is an excellent option in patients who progress to end-stage liver disease. In these patients typical indications for liver transplantation are no different than in other conditions requiring transplantation. Liver transplantation however might be also suggested for specific indications even in patients with otherwise well preserved liver function. 5-year survival after liver transplantation in primary biliary cirrhosis was reported to be between 78 and 87%. Survival rates after liver transplantation in primary sclerosing cholangitis are considered favorable when compared to many other indications for this procedure. Nevertheless, in both primary biliary cirrhosis and primary sclerosing cholangitis recurrence of the disease after liver transplantation can be observed. Cystic fibrosis, biliary atresia, Alagille syndrome and progressive familiar intrahepatic cholestasis are cholestatic conditions in children. Liver transplantation represents an effective treatment in majority of cases fulfilling the criteria for this procedure.

Entities:  

Mesh:

Year:  2012        PMID: 22201783     DOI: 10.2741/3966

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  5 in total

1.  Outcomes of liver transplantation for end-stage biliary disease: A comparative study with end-stage liver disease.

Authors:  Yan-Hua Lai; Wei-Dong Duan; Qiang Yu; Sheng Ye; Nian-Jun Xiao; Dong-Xin Zhang; Zhi-Qiang Huang; Zhan-Yu Yang; Jia-Hong Dong
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

2.  Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients.

Authors:  Mehmet Sayiner; Maria Stepanova; Leyla De Avila; Pegah Golabi; Andrei Racila; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2019-08-27       Impact factor: 3.199

Review 3.  Cirrhosis and autoimmune liver disease: Current understanding.

Authors:  Rodrigo Liberal; Charlotte R Grant
Journal:  World J Hepatol       Date:  2016-10-08

4.  Evaluation of the effects of additional therapy with Berberis vulgaris oxymel in patients with refractory primary sclerosing cholangitis and primary biliary cholangitis: A quasi-experimental study.

Authors:  Zahra Naghibi; Hassan Rakhshandeh; Lida Jarahi; Seyed Mousalreza Hosseini; Mahdi Yousefi
Journal:  Avicenna J Phytomed       Date:  2021 Mar-Apr

5.  Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Ewa Wunsch; Gary L Norman; Malgorzata Milkiewicz; Marcin Krawczyk; Chelsea Bentow; Zakera Shums; Michael Mahler; Steffi Lopens; Dirk Reinhold; Andre Franke; Christoph Schramm; Dirk Roggenbuck; Piotr Milkiewicz
Journal:  Aliment Pharmacol Ther       Date:  2020-11-07       Impact factor: 8.171

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.